Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 330

1.

[Alterations in responses to vaccines in older people].

Autran B.

Rev Mal Respir. 2019 Sep 12. pii: S0761-8425(19)30311-0. doi: 10.1016/j.rmr.2019.07.008. [Epub ahead of print] Review. French.

PMID:
31522947
2.

Short Communication: Extremely Severe CD4 Lymphopenia During HIV-1 Primary Infection.

Bonnet B, Blum L, Charpentier C, Martres P, Ritvo PG, Autran B, Guihot A.

AIDS Res Hum Retroviruses. 2019 Oct;35(10):930-933. doi: 10.1089/AID.2019.0065. Epub 2019 Sep 12.

PMID:
31418284
3.

Ultra-Protective Ventilation Reduces Biotrauma in Patients on Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome.

Rozencwajg S, Guihot A, Franchineau G, Lescroat M, Bréchot N, Hékimian G, Lebreton G, Autran B, Luyt CE, Combes A, Schmidt M.

Crit Care Med. 2019 Nov;47(11):1505-1512. doi: 10.1097/CCM.0000000000003894.

PMID:
31385880
4.

HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial.

Vieillard V, Combadière B, Tubiana R, Launay O, Pialoux G, Cotte L, Girard PM, Simon A, Dudoit Y, Reynes J, Rockstroh J, Garcia F, Gatell J, Devidas A, Yazdanpanah Y, Weiss L, Fätkenheuer G, Autran B, Joyeux D, Gharakhanian S, Debré P, Katlama C.

NPJ Vaccines. 2019 Jun 3;4:25. doi: 10.1038/s41541-019-0117-5. eCollection 2019. Erratum in: NPJ Vaccines. 2019 Aug 13;4:36.

5.

Cynomolgus macaque IL37 polymorphism and control of SIV infection.

Shiina T, Suzuki S, Congy-Jolivet N, Aarnink A, Garchon HJ, Dereuddre-Bosquet N, Vaslin B, Tchitchek N, Desjardins D, Autran B, Lambotte O, Theodorou I, Le Grand R, Blancher A.

Sci Rep. 2019 May 28;9(1):7981. doi: 10.1038/s41598-019-44235-x.

6.

Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection.

Samri A, Charpentier C, Diallo MS, Bertine M, Even S, Morin V, Oudin A, Parizot C, Collin G, Hosmalin A, Cheynier R, Thiébaut R, Matheron S, Collin F, Zoorob R, Brun-Vézinet F, Autran B; ANRS CO5 IMMUNOVIR-2 Study Group.

PLoS Pathog. 2019 May 16;15(5):e1007758. doi: 10.1371/journal.ppat.1007758. eCollection 2019 May.

7.

Dynamics in HIV-DNA levels over time in HIV controllers.

Avettand-Fenoel V, Bayan T, Gardiennet E, Boufassa F, Lopez P, Lecuroux C, Noel N, Trémeaux P, Monceaux V, Autran B, Meyer L, Saez-Cirion A, Lambotte O, Rouzioux C; CODEX ANRS Cohort Study Group.

J Int AIDS Soc. 2019 Jan;22(1):e25221. doi: 10.1002/jia2.25221.

8.

Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.

Colin de Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, Mercier-Delarue S, Even S, Aboulker JP, Molina JM, Autran B, Simon F; ANRS EP46 NOVAA Group.

AIDS. 2018 Oct 23;32(16):2291-2299. doi: 10.1097/QAD.0000000000001963.

PMID:
30096071
9.

HIV.

Ghosn J, Taiwo B, Seedat S, Autran B, Katlama C.

Lancet. 2018 Aug 25;392(10148):685-697. doi: 10.1016/S0140-6736(18)31311-4. Epub 2018 Jul 23. Review.

PMID:
30049419
10.

PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?

Lavolé A, Guihot A, Veyri M, Lambotte O, Autran B, Cloarec N, Le Garff G, Flament T, Cadranel J, Spano JP.

Ann Oncol. 2018 Apr 1;29(4):1065-1066. doi: 10.1093/annonc/mdx817. No abstract available.

PMID:
29346600
11.

What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM.

Bendenoun M, Samri A, Avettand-Fènoël V, Cardinaud S, Descours B, Carcelain G, Mazeron MC, Bergmann JF, Urrutia A, Moris A, Rouzioux C, Simon F, Andre P, Pocard M, Dray X, Mourez T, Vieillard V, Autran B, Barin F, Sellier P.

EBioMedicine. 2018 Jan;27:51-60. doi: 10.1016/j.ebiom.2017.12.003. Epub 2017 Dec 7.

12.

Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.

Guihot A, Marcelin AG, Massiani MA, Samri A, Soulié C, Autran B, Spano JP.

Ann Oncol. 2018 Feb 1;29(2):517-518. doi: 10.1093/annonc/mdx696. No abstract available.

13.

Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status.

Lucar O, Su B, Potard V, Samri A, Autran B, Moog C, Debré P, Vieillard V.

EBioMedicine. 2017 Aug;22:122-132. doi: 10.1016/j.ebiom.2017.07.007. Epub 2017 Jul 11.

14.

HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.

Rouers A, Klingler J, Su B, Samri A, Laumond G, Even S, Avettand-Fenoel V, Richetta C, Paul N, Boufassa F, Hocqueloux L, Mouquet H, Rouzioux C, Lambotte O, Autran B, Graff-Dubois S, Moog C, Moris A; ANRS CO21 Cohort.

EBioMedicine. 2017 Jul;21:158-169. doi: 10.1016/j.ebiom.2017.05.029. Epub 2017 May 31.

15.

Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.

Griesbeck M, Valantin MA, Lacombe K, Samri-Hassimi A, Bottero J, Blanc C, Sbihi Z, Zoorob R, Katlama C, Guiguet M, Altfeld M, Autran B; HepACT-VIH study group.

AIDS. 2017 Jun 1;31(9):1223-1234. doi: 10.1097/QAD.0000000000001455.

PMID:
28492391
16.

HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells.

Xu Y, Phetsouphanh C, Suzuki K, Aggrawal A, Graff-Dubois S, Roche M, Bailey M, Alcantara S, Cashin K, Sivasubramaniam R, Koelsch KK, Autran B, Harvey R, Gorry PR, Moris A, Cooper DA, Turville S, Kent SJ, Kelleher AD, Zaunders J.

Front Immunol. 2017 Apr 21;8:376. doi: 10.3389/fimmu.2017.00376. eCollection 2017.

17.

Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation.

Yong MK, Cameron PU, Slavin M, Morrissey CO, Bergin K, Spencer A, Ritchie D, Cheng AC, Samri A, Carcelain G, Autran B, Lewin SR.

J Infect Dis. 2017 Jun 1;215(11):1684-1694. doi: 10.1093/infdis/jix192.

PMID:
28431019
18.

Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab.

Le Garff G, Samri A, Lambert-Niclot S, Even S, Lavolé A, Cadranel J, Spano JP, Autran B, Marcelin AG, Guihot A.

AIDS. 2017 Apr 24;31(7):1048-1051. doi: 10.1097/QAD.0000000000001429. No abstract available.

PMID:
28350581
19.

iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease.

Sbihi Z, Dossier A, Boutboul D, Galicier L, Parizot C, Emarre A, Hoareau B, Dupin N, Marcelin AG, Oudin A, Fieschi C, Agbalika F, Autran B, Oksenhendler E, Carcelain G.

Blood. 2017 Feb 16;129(7):855-865. doi: 10.1182/blood-2016-06-719716. Epub 2016 Nov 9.

PMID:
28060720
20.

Comprehensive Mass Cytometry Analysis of Cell Cycle, Activation, and Coinhibitory Receptors Expression in CD4 T Cells from Healthy and HIV-Infected Individuals.

Corneau A, Cosma A, Even S, Katlama C, Le Grand R, Frachet V, Blanc C, Autran B.

Cytometry B Clin Cytom. 2017 Jan;92(1):21-32. doi: 10.1002/cyto.b.21502. Review. Erratum in: Cytometry B Clin Cytom. 2017 May;92 (3):236-237.

21.

Reply to Immunometabolism may provide insights into novel mechanisms of HIV reservoir persistence.

Autran B, Pogliaghi M, Katlama C.

AIDS. 2016 Nov 28;30(18):2896-2898. No abstract available.

PMID:
27824629
22.

Perspectives for immunotherapy: which applications might achieve an HIV functional cure?

Vieillard V, Gharakhanian S, Lucar O, Katlama C, Launay O, Autran B, Ho Tsong Fang R, Crouzet J, Murphy RL, Debré P.

Oncotarget. 2016 Jun 21;7(25):38946-38958. doi: 10.18632/oncotarget.7793. Review.

23.

HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.

Gach JS, Gorlani A, Dotsey EY, Becerra JC, Anderson CT, Berzins B, Felgner PL, Forthal DN, Deeks SG, Wilkin TJ, Casazza JP, Koup RA, Katlama C, Autran B, Murphy RL, Achenbach CJ.

PLoS One. 2016 Aug 8;11(8):e0160341. doi: 10.1371/journal.pone.0160341. eCollection 2016.

24.

Polyfunctional HIV-specific T cells in Post-Treatment Controllers.

Samri A, Bacchus-Souffan C, Hocqueloux L, Avettand-Fenoel V, Descours B, Theodorou I, Larsen M, Saez-Cirion A, Rouzioux C, Autran B; ANRS VISCONTI study group.

AIDS. 2016 Sep 24;30(15):2299-302. doi: 10.1097/QAD.0000000000001195.

PMID:
27428742
25.

International AIDS Society global scientific strategy: towards an HIV cure 2016.

Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F; International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J.

Nat Med. 2016 Aug;22(8):839-50. doi: 10.1038/nm.4108. Epub 2016 Jul 11.

26.

[Biological follow-up of patients with HIV treated with anti-PD-1 or anti-PD-L1 for non-small cell bronchial carcinoma: A task group proposal].

Guihot A, Cadranel J, Lambotte O, Lavolé A, Autran B, Spano JP.

Rev Mal Respir. 2016 Jun;33(6):419-21. doi: 10.1016/j.rmr.2016.03.007. Epub 2016 Apr 29. French. No abstract available.

PMID:
27140903
27.

Reduced Oxidative Burst by Primed Neutrophils in the Elderly Individuals Is Associated With Increased Levels of the CD16bright/CD62Ldim Immunosuppressive Subset.

Sauce D, Dong Y, Campillo-Gimenez L, Casulli S, Bayard C, Autran B, Boddaert J, Appay V, Elbim C.

J Gerontol A Biol Sci Med Sci. 2017 Feb;72(2):163-172. doi: 10.1093/gerona/glw062. Epub 2016 Apr 11.

PMID:
27069096
28.

Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.

Caby F, Guihot A, Lambert-Niclot S, Guiguet M, Boutolleau D, Agher R, Valantin MA, Tubiana R, Calvez V, Marcelin AG, Carcelain G, Autran B, Costagliola D, Katlama C.

Clin Infect Dis. 2016 May 15;62(10):1297-1303. doi: 10.1093/cid/ciw076. Epub 2016 Feb 14.

PMID:
26908792
29.

Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir.

Calin R, Hamimi C, Lambert-Niclot S, Carcelain G, Bellet J, Assoumou L, Tubiana R, Calvez V, Dudoit Y, Costagliola D, Autran B, Katlama C; ULTRASTOP Study Group.

AIDS. 2016 Mar 13;30(5):761-9. doi: 10.1097/QAD.0000000000000987.

PMID:
26730568
30.

Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial.

Katlama C, Lambert-Niclot S, Assoumou L, Papagno L, Lecardonnel F, Zoorob R, Tambussi G, Clotet B, Youle M, Achenbach CJ, Murphy RL, Calvez V, Costagliola D, Autran B; EraMune-01 study team.

AIDS. 2016 Jan;30(2):221-30. doi: 10.1097/QAD.0000000000000894.

PMID:
26684819
31.

Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.

Spano JP, Poizot-Martin I, Costagliola D, Boué F, Rosmorduc O, Lavolé A, Choquet S, Heudel PE, Leblond V, Gabarre J, Valantin MA, Solas C, Guihot A, Carcelain G, Autran B, Katlama C, Quéro L.

Ann Oncol. 2016 Mar;27(3):397-408. doi: 10.1093/annonc/mdv606. Epub 2015 Dec 17. Review.

PMID:
26681686
32.

Tackling latency as a barrier to an HIV cure: what next?

Katlama C, Costagliola D, Autran B.

Lancet HIV. 2015 Dec;2(12):e504-5. doi: 10.1016/S2352-3018(15)00230-1. Epub 2015 Nov 17. No abstract available.

PMID:
26614961
33.

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial).

Piroth L, Moinot L, Yeni P, Avettand-Fénoel V, Reynes J, Girard PM, Marchou B, Georget A, Rouzioux C, Autran B, Duvillard L, Chêne G, Fagard C; ANRS 141 TIPI Trial Study Group.

J Antimicrob Chemother. 2016 Feb;71(2):490-6. doi: 10.1093/jac/dkv369. Epub 2015 Nov 14.

PMID:
26568566
34.

Toward a cure for HIV--Seeking effective therapeutic vaccine strategies.

Autran B.

Eur J Immunol. 2015 Dec;45(12):3215-21. doi: 10.1002/eji.201545513. Review.

35.

Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-α Production in Women.

Griesbeck M, Ziegler S, Laffont S, Smith N, Chauveau L, Tomezsko P, Sharei A, Kourjian G, Porichis F, Hart M, Palmer CD, Sirignano M, Beisel C, Hildebrandt H, Cénac C, Villani AC, Diefenbach TJ, Le Gall S, Schwartz O, Herbeuval JP, Autran B, Guéry JC, Chang JJ, Altfeld M.

J Immunol. 2015 Dec 1;195(11):5327-36. doi: 10.4049/jimmunol.1501684. Epub 2015 Oct 30.

36.

HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell Maturation.

Colineau L, Rouers A, Yamamoto T, Xu Y, Urrutia A, Pham HP, Cardinaud S, Samri A, Dorgham K, Coulon PG, Cheynier R, Hosmalin A, Oksenhendler E, Six A, Kelleher AD, Zaunders J, Koup RA, Autran B, Moris A, Graff-Dubois S.

PLoS One. 2015 Oct 26;10(10):e0140978. doi: 10.1371/journal.pone.0140978. eCollection 2015.

37.

Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.

Achenbach CJ, Assoumou L, Deeks SG, Wilkin TJ, Berzins B, Casazza JP, Lambert-Niclot S, Koup RA, Costagliola D, Calvez V, Katlama C, Autran B, Murphy RL; EraMune 02 study team.

Lancet HIV. 2015 Mar;2(3):e82-91. doi: 10.1016/S2352-3018(15)00026-0. Epub 2015 Feb 17.

38.

Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia.

Guihot A, Dentone C, Assoumou L, Parizot C, Calin R, Seang S, Soulié C, Marcelin AG, Calvez V, Autran B, Katlama C, Costagliola D, Carcelain G.

AIDS. 2016 Jan;30(2):327-30. doi: 10.1097/QAD.0000000000000815.

PMID:
26186129
39.

HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.

Andrés C, Plana M, Guardo AC, Alvarez-Fernández C, Climent N, Gallart T, León A, Clotet B, Autran B, Chomont N, Gatell JM, Sánchez-Palomino S, García F.

J Virol. 2015 Sep;89(18):9189-99. doi: 10.1128/JVI.01062-15. Epub 2015 Jun 24.

40.

Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.

Hattab S, Guiguet M, Carcelain G, Fourati S, Guihot A, Autran B, Caby F, Marcelin AG, Costagliola D, Katlama C.

HIV Med. 2015 Oct;16(9):553-62. doi: 10.1111/hiv.12257. Epub 2015 May 6.

41.

Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.

Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, Mélard A, Nembot G, Blanc C, Samri A, Sáez-Cirión A, Hocqueloux L, Lascoux-Combe C, Allavena C, Goujard C, Valantin MA, Leplatois A, Meyer L, Rouzioux C, Autran B; OPTIPRIM ANRS-147 Study Group.

J Antimicrob Chemother. 2015 Jul;70(7):2108-20. doi: 10.1093/jac/dkv084. Epub 2015 Apr 21.

PMID:
25900157
42.

Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia.

Campillo-Gimenez L, Assoumou L, Valantin MA, Pajanirassa P, Villemonteix J, Soulié C, Marcelin AG, Costagliola D, Capeau J, Autran B, Katlama C, Guihot A; ROCnRAL ANRS 157 Study Group.

AIDS. 2015 Apr 24;29(7):853-6. doi: 10.1097/QAD.0000000000000626.

PMID:
25719828
43.

Increased carotid intima-media thickness is not associated with T-cell activation nor with cytomegalovirus in HIV-infected never-smoker patients.

Goulenok T, Boyd A, Larsen M, Fastenackels S, Boccara F, Meynard JL, Hadour N, Samri A, Desvarieux M, Autran B, Appay V, Girard PM, Sauce D; CHIC Study group.

AIDS. 2015 Jan 28;29(3):287-93. doi: 10.1097/QAD.0000000000000539.

PMID:
25686677
44.

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.

Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F.

Gut. 2015 Aug;64(8):1314-26. doi: 10.1136/gutjnl-2014-308943. Epub 2015 Feb 10. Review.

PMID:
25670809
45.

Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.

Deback C, Burrel S, Varnous S, Carcelain G, Conan F, Aït-Arkoub Z, Autran B, Gandjbakhch I, Agut H, Boutolleau D.

Antivir Ther. 2015;20(2):249-54. doi: 10.3851/IMP2818. Epub 2014 Jun 25. Review.

PMID:
25219330
46.

Neutrophils in antiretroviral therapy-controlled HIV demonstrate hyperactivation associated with a specific IL-17/IL-22 environment.

Campillo-Gimenez L, Casulli S, Dudoit Y, Seang S, Carcelain G, Lambert-Niclot S, Appay V, Autran B, Tubiana R, Elbim C.

J Allergy Clin Immunol. 2014 Nov;134(5):1142-52.e5. doi: 10.1016/j.jaci.2014.05.040. Epub 2014 Jul 16.

PMID:
25042982
47.

Characterization of pandemic influenza immune memory signature after vaccination or infection.

Bonduelle O, Carrat F, Luyt CE, Leport C, Mosnier A, Benhabiles N, Krivine A, Rozenberg F, Yahia N, Samri A, Rousset D, van der Werf S, Autran B, Combadiere B.

J Clin Invest. 2014 Jul;124(7):3129-36. doi: 10.1172/JCI74565. Epub 2014 Jun 9.

48.

Blimp-1 overexpression is associated with low HIV-1 reservoir and transcription levels in central memory CD4+ T cells from elite controllers.

de Masson A, Kirilovsky A, Zoorob R, Avettand-Fenoel V, Morin V, Oudin A, Descours B, Rouzioux C, Autran B.

AIDS. 2014 Jul 17;28(11):1567-77. doi: 10.1097/QAD.0000000000000295.

PMID:
24804861
49.

Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients.

Régent A, Autran B, Carcelain G, Cheynier R, Terrier B, Charmeteau-De Muylder B, Krivitzky A, Oksenhendler E, Costedoat-Chalumeau N, Hubert P, Lortholary O, Dupin N, Debré P, Guillevin L, Mouthon L; French Idiopathic CD4 T Lymphocytopenia Study Group.

Medicine (Baltimore). 2014 Mar;93(2):61-72. doi: 10.1097/MD.0000000000000017.

50.

Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection.

Guihot A, Luyt CE, Parrot A, Rousset D, Cavaillon JM, Boutolleau D, Fitting C, Pajanirassa P, Mallet A, Fartoukh M, Agut H, Musset L, Zoorob R, Kirilovksy A, Combadière B, van der Werf S, Autran B, Carcelain G; FluBAL Study Group.

Am J Respir Crit Care Med. 2014 May 15;189(10):1240-9. doi: 10.1164/rccm.201311-2071OC.

PMID:
24646009

Supplemental Content

Loading ...
Support Center